Related-Party Transactions

12 Months Ended

Dec. 31, 2024

Related-Party Transactions [Abstract]

Related-Party Transactions

(12) Related‑Party Transactions

In November 2023, the Company issued unsecured convertible notes and accompanying Series A and Series B Warrants (see Note 7). The transaction included issuance of a $5 million convertible note and Series A and Series B Warrants to PharmaCyte Biotech, Inc. The interim CEO, President and Director of PharmaCyte Biotech, Inc., Joshua Silverman, serves on the Company’s board of directors. The Series B Warrants expired in November 2024. In November 2024 the Company paid PharmaCyte accrued interest on the convertible note of $300,000 in equity of 315,790 common shares.

During the years ended December 31, 2024 and 2023, a family member of the CEO earned total cash compensation of $168,000 and $138,000, respectively.